Researchers from the Netherlands have uncovered a new gene expression signature linked to ovarian cancer survival that is providing hints about potential pathways of importance for the disease. But authors warn that using such signatures for guiding treatment may be a ways off.
Affy aims to target downstream genomic-analysis markets with the products gained through its acquisitions of Panomics and True Materials last year, roll out new genotyping assays on its GeneTitan array platform, and consolidate its manufacturing facilities.
The activities are part of Kreatech's makeover from a biotech specializing in FISH probes and labeling kits, to a molecular diagnostics company with expertise in oncology, hematology, and constitutional disorders.
A team of Ontario researchers has identified a six-gene signature that can help predict non-small cell lung cancer outcomes — and uncovered evidence that there may be thousands of alternative prognostic signatures for the disease.
Small (and not-so-small) noncoding RNAs have thrown a spanner in the works of understanding genome function. We take a look at the major questions brought about by micro-RNA, Piwi-interacting RNA, and more.
Trey Ideker says the real value of gene expression data is determining which pathways are critical to a particular disease. In his cancer studies, the pathway-based approach could become a new kind of biomarker.